{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:12:42Z","timestamp":1793725962081,"version":"4.6.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T00:00:00Z","timestamp":1537401600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","award":["Not attributed"],"award-info":[{"award-number":["Not attributed"]}],"id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12882-018-1045-8","type":"journal-article","created":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T11:39:48Z","timestamp":1537443588000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1537-5302","authenticated-orcid":false,"given":"Jesse M. G.","family":"Hofman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele F.","family":"Eisenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adry","family":"Diepenbroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilja M.","family":"Nolte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastiaan","family":"van Dam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Westerhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan J. L.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casper F. M.","family":"Franssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo A. J. M.","family":"Gaillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,20]]},"reference":[{"key":"1045_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084943","volume":"9","author":"ME Stauffer","year":"2014","unstructured":"Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One. 2014;9:e84943. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0084943\n                    \n                  .","journal-title":"PLoS One"},{"key":"1045_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2337\/diaspect.21.1.12","volume":"21","author":"NB O\u2019Mara","year":"2010","unstructured":"O\u2019Mara NB. Anemia in patients with chronic kidney disease. Diabetes Spectr. 2010;21:12\u20139.","journal-title":"Diabetes Spectr"},{"key":"1045_CR3","doi-asserted-by":"publisher","DOI":"10.1017\/S1368980008002401","volume-title":"Worldwide prevalence of anaemia 1993\u20132005","author":"B de Benoist","year":"2008","unstructured":"de Benoist B, McLean E, Egli I, Cogswell M. Worldwide prevalence of anaemia 1993\u20132005. Geneva: WHO Press, world health organization; 2008. \n                    https:\/\/doi.org\/10.1017\/S1368980008002401\n                    \n                  ."},{"key":"1045_CR4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1503\/cmaj.071131","volume":"179","author":"R Zarychanski","year":"2008","unstructured":"Zarychanski R, Houston DS. Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response? CMAJ. 2008;179:333\u20137. \n                    https:\/\/doi.org\/10.1503\/cmaj.071131\n                    \n                  .","journal-title":"CMAJ"},{"key":"1045_CR5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1185\/03007990903512461","volume":"26","author":"IC Macdougall","year":"2010","unstructured":"Macdougall IC. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous? Curr Med Res Opin. 2010;26:473\u201382.","journal-title":"Curr Med Res Opin"},{"key":"1045_CR6","first-page":"108","volume":"73","author":"NC van der Weerd","year":"2015","unstructured":"van der Weerd NC, Grooteman MPC, Nub\u00e9 MJ, ter Wee PM, Swinkels DW, Gaillard CAJM. Hepcidin in chronic kidney disease: not an anaemia management tool, but promising as a cardiovascular biomarker. Neth J Med. 2015;73:108\u201318.","journal-title":"Neth J Med"},{"key":"1045_CR7","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1126\/science.1104742","volume":"306","author":"E Nemeth","year":"2004","unstructured":"Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090\u20133. \n                    https:\/\/doi.org\/10.1126\/science.1104742\n                    \n                  .","journal-title":"Science"},{"key":"1045_CR8","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1053\/j.ajkd.2007.03.007","volume":"49","author":"S Fishbane","year":"2007","unstructured":"Fishbane S. Iron Management in Nondialysis-Dependent CKD. Am J Kidney Dis. 2007;49:736\u201343.","journal-title":"Am J Kidney Dis"},{"key":"1045_CR9","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1053\/j.ajkd.2008.05.033","volume":"52","author":"B Rozen-Zvi","year":"2008","unstructured":"Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U. Intravenous versus Oral Iron supplementation for the treatment of Anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis. 2008;52:897\u2013906. \n                    https:\/\/doi.org\/10.1053\/j.ajkd.2008.05.033\n                    \n                  .","journal-title":"Am J Kidney Dis"},{"key":"1045_CR10","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","volume":"29","author":"IC Macdougall","year":"2014","unstructured":"Macdougall IC, Bock AH, Carrera F, Eckardt K-U, Gaillard C, Van Wyck D, et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant. 2014;29:2075\u201384. \n                    https:\/\/doi.org\/10.1093\/ndt\/gfu201\n                    \n                  .","journal-title":"Nephrol Dial Transplant"},{"key":"1045_CR11","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1053\/j.ajkd.2016.04.018","volume":"68","author":"D Shepshelovich","year":"2016","unstructured":"Shepshelovich D, Rozen-Zvi B, Avni T, Gafter U, Gafter-gvili A. Intravenous versus Oral Iron supplementation for the treatment of Anemia in CKD: an updated systematic review and meta-analysis. Am J Kidney Dis. 2016;68:677\u201390. \n                    https:\/\/doi.org\/10.1053\/j.ajkd.2016.04.018\n                    \n                  .","journal-title":"Am J Kidney Dis"},{"key":"1045_CR12","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1681\/ASN.2006080856","volume":"18","author":"WH H\u00f6rl","year":"2007","unstructured":"H\u00f6rl WH. Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol. 2007;18:382\u201393. \n                    https:\/\/doi.org\/10.1681\/ASN.2006080856\n                    \n                  .","journal-title":"J Am Soc Nephrol"},{"key":"1045_CR13","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1111\/j.1523-1755.2005.00758.x","volume":"68","author":"DB Van Wyck","year":"2005","unstructured":"Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005;68:2846\u201356.","journal-title":"Kidney Int"},{"key":"1045_CR14","volume-title":"Richtlijn Anemie bij Chronische Nierziekte","author":"Y Smets","year":"2015","unstructured":"Smets Y, Gaillard C. Richtlijn Anemie bij Chronische Nierziekte. 1st ed. Amsterdam: Nederlandse federatie voor Nefrologie; 2015.","edition":"1"},{"key":"1045_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ejim.2017.04.018","volume":"42","author":"FL De","year":"2017","unstructured":"De FL, Iolascon A, Taher A, Domenica M. European journal of internal medicine clinical management of iron de fi ciency anemia in adults\u00a0: systemic review on advances in diagnosis and treatment. Eur J Intern Med. 2017;42:16\u201323. \n                    https:\/\/doi.org\/10.1016\/j.ejim.2017.04.018\n                    \n                  .","journal-title":"Eur J Intern Med"},{"key":"1045_CR16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/kisup.2012.37","volume":"2","author":"Kidney Disease: Improving global outcomes (KDIGO) Anemia work group","year":"2012","unstructured":"Kidney Disease: Improving global outcomes (KDIGO) Anemia work group. KDIGO clinical practice guideline for Anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:279\u2013335.","journal-title":"Kidney Int Suppl"},{"key":"1045_CR17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/MOH.0b013e32835f5933","volume":"20","author":"C Brugnara","year":"2013","unstructured":"Brugnara C, Mohandas N. Red cell indices in classification and treatment of anemias: from M.M. Wintrobes\u2019s original 1934 classification to the third millennium. Curr Opin Hematol. 2013;20:222\u201330. \n                    https:\/\/doi.org\/10.1097\/MOH.0b013e32835f5933\n                    \n                  .","journal-title":"Curr Opin Hematol"},{"key":"1045_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/pharmaceutics3010012","volume":"3","author":"P Geisser","year":"2011","unstructured":"Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics. 2011;3:12\u201333. \n                    https:\/\/doi.org\/10.3390\/pharmaceutics3010012\n                    \n                  .","journal-title":"Pharmaceutics"},{"issue":"suppl 2","key":"1045_CR19","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1097\/01.ASN.0000143814.49713.C5","volume":"15","author":"BG Danielson","year":"2004","unstructured":"Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol. 2004;15(suppl 2):S93\u20138. \n                    https:\/\/doi.org\/10.1097\/01.ASN.0000143814.49713.C5\n                    \n                  .","journal-title":"J Am Soc Nephrol"},{"key":"1045_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00775-007-0297-8","volume":"13","author":"RW Evans","year":"2008","unstructured":"Evans RW, Rafique R, Zarea A, Rapisarda C, Cammack R, Evans PJ, et al. Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera. J Biol Inorg Chem. 2008;13:57\u201374. \n                    https:\/\/doi.org\/10.1007\/s00775-007-0297-8\n                    \n                  .","journal-title":"J Biol Inorg Chem"},{"key":"1045_CR21","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/ndt\/gft251","volume":"29","author":"JE Onken","year":"2014","unstructured":"Onken JE, Bregman DB, Harrington RA, Morris D, Buerkert J, Hamerski D, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transplant. 2014;29:833\u201342. \n                    https:\/\/doi.org\/10.1093\/ndt\/gft251\n                    \n                  .","journal-title":"Nephrol Dial Transplant"},{"key":"1045_CR22","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1053\/j.gastro.2011.06.005","volume":"141","author":"R Evstatiev","year":"2011","unstructured":"Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141:846\u2013853.e2.","journal-title":"Gastroenterology"},{"key":"1045_CR23","doi-asserted-by":"publisher","first-page":"468675","DOI":"10.1155\/2015\/468675","volume":"2015","author":"S Hardy","year":"2015","unstructured":"Hardy S, Vandemergel X. Intravenous iron administration and hypophosphatemia in clinical practice. Int J Rheumatol. 2015;2015:468675. \n                    https:\/\/doi.org\/10.1155\/2015\/468675\n                    \n                  .","journal-title":"Int J Rheumatol"},{"key":"1045_CR24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s11255-011-0028-5","volume":"44","author":"P Van Buren","year":"2012","unstructured":"Van Buren P, Velez RL, Vaziri ND, Zhou XJ. Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD. Int Urol Nephrol. 2012;44:499\u2013507. \n                    https:\/\/doi.org\/10.1007\/s11255-011-0028-5\n                    \n                  .","journal-title":"Int Urol Nephrol"},{"key":"1045_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40265-014-0332-3","volume":"75","author":"GM Keating","year":"2015","unstructured":"Keating GM. Ferric Carboxymaltose: a review of its use in Iron deficiency. Drugs. 2015;75:101\u201327. \n                    https:\/\/doi.org\/10.1007\/s40265-014-0332-3\n                    \n                  .","journal-title":"Drugs"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-1045-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-018-1045-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-1045-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T19:05:14Z","timestamp":1568919914000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-018-1045-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,20]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1045"],"URL":"https:\/\/doi.org\/10.1186\/s12882-018-1045-8","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,20]]},"assertion":[{"value":"13 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A waiver was obtained for this research from the medical ethical committee in the UmcG for the act on Medical Research Involving Human Subjects (in Dutch:WMO).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"C.A.J.M.G. received speaking fees and research funding from Vifor Pharma. The other authors have declared that no conflict of interest exists.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"242"}}